ENG19

Advanced solid tumors expressing EGFR

Phase 1/IIaActive

Key Facts

Indication
Advanced solid tumors expressing EGFR
Phase
Phase 1/IIa
Status
Active
Company

About EnGeneIC

Australian biotech leveraging nanocell cyto‑immunotherapy to deliver targeted cancer treatments.

View full company profile

Therapeutic Areas